What You Need to Know About Optimizing Cardiorenal Outcomes with Novel NonSteroidal MRAs

This activity is jointly provided by Global Education Group and Cardiometabolic Health Congress.

This activity is supported by an educational grant from Bayer HealthCare Pharmaceuticals Inc.

Program Overview

Release Date: February 1, 2023
Expiration Date: February 1, 2024

During this recorded symposium from the 2022 American Heart Association (AHA), you will get a chance to:

• Learn more about the importance of chronic kidney disease and type 2 diabetes as major drivers of cardiovascular morbidity and mortality
• Be up-to-date about the data with novel nonsteroidal MRAs in cardiorenal risk reduction, and how this new approach fits in with existing treatment options
• Hear from top-experts on how to apply this evidence to reduce the risk of cardiovascular and renal adverse events in patients with chronic kidney disease and type 2 diabetes

Learning Objectives:

After completing this activity, the participant should be better able to:

• Recognize the burden of comorbid CKD and T2DM as a major driver of cardiovascular and renal morbidity and mortality.
• Identify T2DM patients at risk for kidney disease or kidney disease progression based on recommended diagnostic practices.
• Summarize the efficacy, safety, and mechanisms of action of nonsteroidal MRAs and other emerging treatment options for DKD.
• Select tailored treatment regimens that reduce the risk of cardiorenal adverse events in T2DM patients with CKD.

---

Target Audience

The educational design of this activity addresses the needs of US-based cardiologists, primary care physicians, endocrinologists, lipidologists as well as nurses, nurse practitioners, and pharmacists.

---

Faculty

George L. Bakris, MD
Professor of Medicine
Director, ASH Comprehensive Hypertension Center
University of Chicago Medicine
Chicago, IL

Dr. Bakris discloses the following:
Consulting Fee: Merck, Bayer, KBP Biosciences, Ionis, Alnylam, Astra Zeneca, Quantum Genomics, Horizon, Novo Nordisk, Dia Medica Therapeutics

Rajiv Agarwal, MD
Professor of Medicine
Indiana University School of Medicine & VA Medical Center
Indianapolis, IN

Dr. Agarwal discloses the following:
Consulting Fee: Bayer, Boehringer, Akebia, Chinook, Vertex
Contracted Research: Bayer, Boehringer, Akebia, Chinook, Vertex

Sylvia E. Rosas, MD, MSCE
Associate Professor of Medicine
Joslin Diabetes CenterHarvard Medical School
Boston, MA

Dr. Rosas discloses the following:
Employee: Joslin Diabetes Center-Beth Israel Lahey
Consulting Fee: Bayer Healthcare, AstraZeneca, Travere
Contracted Research: Bayer Healthcare, AstraZeneca
Honoraria: Bayer Healthcare

Pam R. Taub, MD, FACC, FASPC
Professor of Medicine
Director, Step Family Foundation Cardiac
Rehabilitation and Wellness Center
UC San Diego
San Diego, CA

Dr. Taub discloses the following:
Consulting Fee (e.g., Advisory Board): Amgen, Bayer, Boehringer-Ingelheim, Esperion therapeutics, Medtronic, Novartis, Novo-Nordisk, Sanofi
Honororia: Epirium Bio
Contracted Research: Applied Therapeutics

---

JOINT PROVIDERSHIP STATEMENT

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Cardiometabolic Health Congress. Global is accredited by the ACCME to provide continuing medical education for physicians.

PHYSICIAN CONTINUING EDUCATION

Global Education Group designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

NURSING CONTINUING EDUCATION

Global Education Group is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

This educational activity for 1.5 contact hours is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

PHARMACY CONTINUING EDUCATION

Global Education Group is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education with Commendation.

Credit Designation

Global Education Group designates this continuing education activity for 1.5 contact hour(s) (0.10 CEUs) of the Accreditation Council for Pharmacy Education.

Universal Activity Number (UAN): 0530-9999-22-241-H01-P.

This is a knowledge-based activity.

---

Instructions for Participation

This activity is complimentary and available during the period February 1, 2023 through February 1, 2024. Participants must read the learning objectives and faculty disclosures, study the educational activity, obtain a score of 70% or better on the post-test, and complete the evaluation. Upon completing, your certificate will be available for print.

For questions about the accreditation of this activity, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

For Pharmacists: Please complete the evaluation instructions above. Upon registering and completing the activity evaluation, your transcript information will be sent to the NABP CPE Monitor Service within 4-6 weeks.

---

DISCLOSURES

Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The planners and managers have the following relevant financial relationships with ineligible companies:

Name of Planner or Manager and Reported Financial Relationship
Rhys Williams, MSN, FNP-C, RN
Nothing to disclose.

Lauren Sinclair
Nothing to disclose.

Lindsay Borvansky
Nothing to disclose.

Liddy Knight
Nothing to disclose.

Andrea Funk
Nothing to disclose.

Ashley Cann
Nothing to disclose.

Deborah Sharkey
Nothing to disclose.

Kelly Pechous
Nothing to disclose.

Karin McAdams
Nothing to disclose.

Shpetim Karandrea, PhD
Nothing to disclose.

Neha Agarwal, PhD
Nothing to disclose.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and Cardiometabolic Health Congress do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.